Catalyst Pharmaceuticals to Announce Q2 2024 Financial Results on August 7, 2024

Catalyst Pharmaceuticals, Inc., a specialist in developing and commercializing treatments for rare and hard-to-treat diseases, will disclose its financial performance for the second quarter of 2024 on August 7, 2024. The announcement will be made post-market hours. The company’s executive team will subsequently hold a conference call and webcast the following day, August 8, 2024, at 8:30 AM ET, to discuss these results and provide a business update. Interested parties can access the webcast through the Investors section on Catalyst’s website, where a replay will be available for 30 days.

Catalyst Pharmaceuticals is dedicated to introducing innovative, first-in-class medicines to address the needs of patients with rare diseases. Their principal U.S. product, FIRDAPSE® (amifampridine) Tablets 10 mg, is approved for treating Lambert-Eaton myasthenic syndrome (LEMS) in adults and children aged six and older. In January 2023, Catalyst expanded its portfolio by acquiring the U.S. rights to FYCOMPA® (perampanel) CIII. This medication is prescribed for epilepsy patients aged four and above, either as a standalone treatment or in conjunction with other drugs to address partial-onset seizures and other generalized seizures.

Health Canada has also sanctioned FIRDAPSE for treating adult LEMS patients in Canada. On July 18, 2023, Catalyst secured an exclusive North American license for AGAMREE® (vamorolone), an oral suspension for Duchenne Muscular Dystrophy. AGAMREE has been granted Orphan Drug and Fast Track designations by the FDA and received approval for U.S. commercialization on October 26, 2023. This medication became available by prescription in the U.S. starting March 13, 2024.

Catalyst Pharmaceuticals continues to be a patient-centric organization, focused on developing life-changing therapies for rare diseases. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!